Novartis Triple Combo Enerzair Gets EU OK For Asthma
Nudges Ahead Of GSK's Trelegy in Europe
The Swiss company's asthma triplet is now approved in Europe and Japan but Enerzair is well behind GSK's rival LABA/LAMA/ICS in the US where Novartis's product has not even been submitted yet.
You may also be interested in...
Trelegy, already approved for COPD, will be targeted to the roughly one-third of asthmatics not controlled on maintenance therapy.
The Japanese firm with R&D operations in the UK is conducting a search to find "a potentially transformative acquisition," helped by a significant financing round.
Japan’s regulators have approved a large batch of new products, including a novel antibody from Chugai, two world-first nods for the country’s second HIF-PH inhibitors and an asthma therapy, and the first Humira biosimilar in Japan – as well as five drugs from Novartis.